GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Float Percentage Of Total Shares Outstanding

Achilles Therapeutics (STU:698) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Achilles Therapeutics's float shares is 0.00 Mil. Achilles Therapeutics's total shares outstanding is 42.70 Mil. Achilles Therapeutics's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Achilles Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Achilles Therapeutics's Institutional Ownership is 0.30%.

Achilles Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Achilles Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/42.70
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achilles Therapeutics (STU:698) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
NERV INKT PVCT COEP PASG HOOK VTVT EFTR CGTX SLGL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ACHL:USA 698:Germany
Address
245 Hammersmith Road, London, GBR, W6 8PW
Website
https://www.achillestx.com
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines